Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
This is the summary MarketWatch.com - Top Stories published in their feed. The article itself is on their site.
Read the full article at marketwatch.com